Welcome to the healthcare professional section of Sycrest.co.uk
Sycrest (asenapine) is the first tetracyclic antipsychotic therapy for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Sycrest is the first tetracyclic antipsychotic with a unique receptor profile:
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Lundbeck Limited, Medical Information, on: 01908 638972.
Last updated December 2012